Investing in a new treatment for dyskinesia Date 24 January 2018 We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.
Research into flu and the onset of Parkinson's Date 16 January 2018 A study, featured in the Daily Mail, suggests a link between certain types of flu and risk of Parkinson's.
More than 12,000 Scots living with Parkinson's and numbers continue to rise Date 8 January 2018 New figures from Parkinson's UK show that more than 12,000 Scots are now living with Parkinson's, and numbers are continuing to rise.
Parkinson's diagnoses set to increase by a fifth by 2025 Date 8 January 2018 The number of people diagnosed and living with Parkinson’s is increasing, according to our latest research.
Research on caffeine to diagnose Parkinson's Date 4 January 2018 Researchers in Japan have discovered that people with Parkinson's may have lower levels of caffeine in their blood after drinking tea and coffee.
Meet the woman who can smell Parkinson's Date 20 December 2017 A Parkinson's UK-funded study, inspired by a woman's ability to smell the condition, has resulted in the discovery of 10 molecules which could lead to the first diagnostic test for Parkinson's.
Caption Gary (who has Parkinson's), Ernest and Amy Berry at the 2017 Parkinson's UK Parliamentary reception Keeping Parkinson's on the political agenda Date 14 December 2017 A round-up of our activities with politicians to keep Parkinson's on their agenda.
Tapeworm drug shows promise for Parkinson's Date 12 December 2017 Research supported by Parkinson's UK has identified a medicine used to treat tapeworm infections which could lead to new treatments for people with Parkinson's.
Live Loud – a project to shout about Date 8 December 2017 It's one year on and our Live Loud! volunteers in Wales continue to make a real difference to people whose voices have been affected by Parkinson's.
Further evidence on the benefits of pimavanserin Date 25 September 2017 UK researchers publish further evidence highlighting the need to licence pimavanserin for hallucinations and delusions in Parkinson's.
